Post by nylefty on Mar 23, 2016 15:28:57 GMT -5
This exchange was on MannKind's Facebook page. Interesting.
Otto Bjorn: what they need is to break into the anti-nausea market-combine ts with zofran or similar drugs-delivering these by inhalation would be a home run for rapid action,no iv needed,and bypassing the (vomiting)gi tract
March 18 at 5:45pm
MannKind Corporation: Otto: I was able to confirm with our Chief Medical Officer the following: Palonosetron is the best in class for the 5HT3 drugs (these are the Zofran-like drugs), and MannKind believes it to be well suited for Technosphere delivery. It is currently in development within our R&D group.
March 21 at 11:06pm
www.facebook.com/MannKind-Corporation-237759248628/
Otto Bjorn: what they need is to break into the anti-nausea market-combine ts with zofran or similar drugs-delivering these by inhalation would be a home run for rapid action,no iv needed,and bypassing the (vomiting)gi tract
March 18 at 5:45pm
MannKind Corporation: Otto: I was able to confirm with our Chief Medical Officer the following: Palonosetron is the best in class for the 5HT3 drugs (these are the Zofran-like drugs), and MannKind believes it to be well suited for Technosphere delivery. It is currently in development within our R&D group.
March 21 at 11:06pm
www.facebook.com/MannKind-Corporation-237759248628/
